Search Medical Condition
Please enter condition
Please choose location from dropdown

Champion, Belgium Clinical Trials

A listing of Champion, Belgium clinical trials actively recruiting patients volunteers.

RESULTS

Found (70) clinical trials

Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer

Prostate cancer patients for which reimbursed ADT with a gonadoliberin antagonist is indicated, for a period of at least 6 months will lbe enrolled. At 0, 3 months and 6 months of ADT, Aging Males' Symptoms (AMS), EQ-5D (EuroQoL), and hot flashes intensity and frequency (Moyad scale) will be collected, ...

Phase N/A

1.29 miles

Learn More »

Inter Scorers Agreement for OSA Screening Scores.

Four scores are usually performed to detect OSA (Obstructive Sleep Apnea) patients. These four scores are: STOP-Bang, P-SAP, OSA50 and DES-OSA. These scores have been previously validated. However, a comparison between scorers in the realization of these scores has never been performed. The aim of this study was to evaluate ...

Phase N/A

1.29 miles

Learn More »

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.

This is a phase II , openlabel, randomized study in patients with confirmed diagnosis of resectable metastatic colorectal adenocarcinoma , who have not received prior chemotherapy for their metastatic disease. The study is designed to compare pathological responses observed after pre-operative chemotherapy bevacizumab with FOLFOX or FOLFIRI.

Phase

1.7 miles

Learn More »

A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Phase N/A

1.7 miles

Learn More »

Influence of Different Methods of Measurement in the Accuracy of DES-OSA and P-SAP Scores

DES-OSA and P-SAP scores have been validated to detect OSA (Obstructive Sleep Apnea). One item of P-SAP and DES-OSA is the measurement of neck circumference. The aim of this study is to compare the influence of different methods of neck circumference measurement in the accuracy of DES-OSA and P-SAP scores ...

Phase N/A

1.7 miles

Learn More »

Influence of Different Parameters on Exhumation Time After Cardiac Surgery.

The aim of this study is to determine which factors could be at risk of delayed extubation after cardiac surgery. Several parameters of ventilation and infusion were recorded during surgery. A statistical analysis will be performed to determine if one of many of these are significant. The investigator does not ...

Phase N/A

1.7 miles

Learn More »

Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer

Patients with histological confirmed colon adenocarcinoma compatible with clinical stage II or III are eligible for study screening. Receipt of a signed informed consent and study inclusion should be done within 15 days after histological diagnosis. A usual workup for preoperative staging of colon cancer must be done not more ...

Phase N/A

1.7 miles

Learn More »

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT ...

Phase

2.36 miles

Learn More »

A Study to Evaluate the Safety Efficacy and Pharmacokinetics of ARGX-113 in Patients With ITP

This is a randomized, double-blind, placebo-controlled Phase II study in which approximately 36 patients will be randomized in a 1:1:1 ratio to receive either ARGX-113 Dose A, or ARGX-113 Dose B body weight or placebo in 4 infusions administered 1-week apart in addition to Standard-of-Care (SoC) treatment. Patients aged 18 ...

Phase

2.36 miles

Learn More »

A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Phase

2.36 miles

Learn More »